StockNews.com began coverage on shares of Agile Therapeutics (NASDAQ:AGRX – Free Report) in a research report report published on Friday. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.
Separately, Maxim Group raised Agile Therapeutics from a hold rating to a buy rating and set a $5.00 target price on the stock in a research report on Friday, September 22nd.
Agile Therapeutics Price Performance
Institutional Investors Weigh In On Agile Therapeutics
Hedge funds have recently bought and sold shares of the company. Renaissance Technologies LLC boosted its holdings in Agile Therapeutics by 281.3% in the 1st quarter. Renaissance Technologies LLC now owns 621,200 shares of the specialty pharmaceutical company’s stock valued at $130,000 after purchasing an additional 458,300 shares during the period. BlackRock Inc. increased its holdings in shares of Agile Therapeutics by 538.6% during the third quarter. BlackRock Inc. now owns 303,799 shares of the specialty pharmaceutical company’s stock worth $91,000 after buying an additional 256,227 shares in the last quarter. Virtu Financial LLC bought a new position in shares of Agile Therapeutics in the 4th quarter valued at $32,000. Jane Street Group LLC acquired a new stake in shares of Agile Therapeutics during the 2nd quarter valued at $108,000. Finally, State Street Corp acquired a new position in shares of Agile Therapeutics in the second quarter valued at approximately $32,000. 7.52% of the stock is currently owned by institutional investors and hedge funds.
About Agile Therapeutics
Agile Therapeutics, Inc, a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.
- Five stocks we like better than Agile Therapeutics
- The 3 Best Retail Stocks to Shop for in August
- The most upgraded stocks in November have two things in common
- Are Stock Buybacks Good for the Average Investor?
- Monday.com rocked earnings like it’s the weekend
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Plan to own one retailer? Make it this one
Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.